Personalis, Inc. (PSNL)
NASDAQ: PSNL · Real-Time Price · USD
4.830
+0.260 (5.69%)
At close: Aug 13, 2025, 4:00 PM
4.720
-0.110 (-2.28%)
Pre-market: Aug 14, 2025, 9:05 AM EDT
Personalis Revenue
Personalis had revenue of $17.20M in the quarter ending June 30, 2025, a decrease of -23.81%. This brings the company's revenue in the last twelve months to $80.32M, up 0.36% year-over-year. In the year 2024, Personalis had annual revenue of $84.61M with 15.15% growth.
Revenue (ttm)
$80.32M
Revenue Growth
+0.36%
P/S Ratio
4.66
Revenue / Employee
$350,729
Employees
229
Market Cap
428.31M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
PSNL News
- 8 days ago - Super Micro Computer Posts Downbeat Q4 Results, Joins Personalis, Snap And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
- 8 days ago - Personalis, Inc. (PSNL) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 8 days ago - Personalis Reports Second Quarter 2025 Financial Results - Business Wire
- 22 days ago - Personalis to Announce Second Quarter 2025 Financial Results - Business Wire
- 26 days ago - Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 5 weeks ago - Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients - Business Wire
- 2 months ago - Personalis' NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO - Business Wire
- 2 months ago - New Data Shows NeXT Personal® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse - Business Wire